---

Chapter 2: Principles of Epidemiology - Complete Answers (Park's Textbook)

---

LONG & SHORT ANSWER QUESTIONS

---

Q1. Tamralipto / Purba Medinipur: Acute Gastroenteritis Outbreak after Community Feast

---

• Clinically examine a sample of cases presenting with acute gastroenteritis (vomiting, diarrhoea, abdominal cramps)
• Collect stool samples for bacteriological examination (Salmonella, E. coli, Vibrio, Shigella, etc.)
• Epidemiological investigation should NOT be delayed until lab results are available

• Compare current disease frequency with the same period in previous years
• In this case (85 cases in 3 days following a feast), a common-source epidemic is obvious needing no statistical comparison - this is easily recognized as an epidemic

• Obtain a detailed map of the village
• Count total population by house-to-house visits; note all who attended the community feast
• Calculate the denominator (population at risk = all who attended the feast)

• Conduct a medical survey of the entire village, including non-attendees
• Prepare an epidemiological case sheet collecting: name, age, sex, occupation, foods eaten at the feast, time of onset, symptoms, water and milk consumption history, personal contacts
• Search for missed/unreported cases (at homes, PHC, hospitals)

• Draw an Epidemic Curve: Plot number of cases by time of onset - a common-source epidemic (point source from the feast) will show a sharp bell-shaped peak within one incubation period
• Calculate Attack Rates (total ill / total exposed × 100) for different foods consumed at the feast (food-specific attack rates)
• Describe cases by Person (age, sex, who attended feast), Place (mapping of cases), Time (onset pattern)

• Based on the food-specific attack rates, identify the implicated food item (the food with highest attack rate among those who ate it and lowest among those who did not)

• Use a case-control study or retrospective cohort study among feast attendees to statistically confirm the association between consumption of the implicated food and illness
• Laboratory confirmation: culture of implicated food, stool cultures

• Examine food preparation methods, storage conditions, cook's health status, water supply, and sanitary facilities at the feast venue

• Document findings, conclusions, and recommendations for public health authorities

---

1. Treatment of cases: Oral Rehydration Therapy (ORS) for dehydration; severe cases referred to hospital
2. Stop the identified source: Destroy/withdraw suspected food items; close the implicated food source
3. Safe water supply: Ensure chlorination of drinking water; distribute ORS sachets
4. Health education: Advise on hand hygiene, safe food practices, boiling of water
5. Notification: Report to the CMOH/BMOH as per disease surveillance protocols
6. Environmental sanitation: Immediate attention to waste disposal and latrine use

---

Q2. Prevalence of Obesity among Medical Students - Study Design (Barasat GMC) [2+13=15]

1. Define the study population: All medical students of the institution (MBBS all batches, perhaps Phase 1, 2, 3)
2. Determine sample size: Using prevalence formula: n = Z²pq/d² (use estimated prevalence of obesity ~15-20%, confidence interval 95%, allowable error 5%). Apply appropriate sampling frame.
3. Sampling technique: Stratified random sampling (stratify by year/batch), then systematic or simple random sampling
4. Define obesity: Use Body Mass Index (BMI) ≥30 kg/m² (WHO criteria); or BMI ≥25 for Asian Indians
5. Develop data collection tool: Structured pretested questionnaire covering demographic data, dietary habits, physical activity, sedentary behaviour (screen time), medical history; plus anthropometric measurements
6. Ethical approval: Obtain Institutional Ethics Committee clearance; informed consent from all participants
7. Data collection: Measure weight (kg), height (m), waist circumference; administer questionnaire
8. Quality control: Train investigators, pre-test instruments, double data entry
9. Data analysis: Calculate prevalence of obesity; compute frequency tables; use chi-square for association; logistic regression for determinants
10. Interpretation and report: Compare findings with national/state data; report to institution

---

Q3. 85 Cases Diarrhoeal Disease - Epidemic or Outbreak? Study Design, Control Measures (Midnapore) [2+8+3+2=15]

• Epidemic: Occurrence in a community clearly in excess of normal expectancy; usually applied to larger geographic areas
• Outbreak: WHO defines it as more restricted in scope - often used for a limited geographic area or institution (a village feast context). In practice, the 85 cases within 3 days limited to those attending one community feast is best called an outbreak - it is a point-source (common-source) outbreak, limited to feast attendees in one village

• All feast attendees = cohort
• Classified as exposed/unexposed to each food item
• Attack rates calculated for each food
• Relative Risk (RR) calculated for each food item
• Food with highest RR and statistically significant association = implicated source
• Alternatively, a case-control study if the total number of attendees is not known

1. Oral Rehydration Therapy (ORS) and IV fluids for severe dehydration; hospitalize critical cases
2. Remove/destroy remaining suspected food items; enforce boiling of water; hand hygiene education

---

Q4. Acute Watery Diarrhoea - 45 admitted, 2 deaths; Attack Rate, Sanitation Plan (Barasat GMC) [6+4+5=15]

• Total population = 1,500
• Cases = 45
• Attack Rate = 45/1,500 × 100 = 3%

• Chlorination/disinfection of all drinking water sources (wells, hand pumps)
• Boiling of drinking water advisory
• Disinfection of suspected food sources / removal
• Proper disposal of vomitus and excreta of patients (chlorinated lime)
• Personal hygiene: hand washing with soap promotion

• Construction and use of sanitary latrines (total sanitation campaign - Swachh Bharat Mission)
• Safe piped water supply to all households
• Construction of soak pits and proper sewage disposal systems
• Health education about safe food handling, hygiene, and water purification
• Food safety regulations for community feasts (mandatory medical fitness of cooks, food safety inspection)
• Regular surveillance and monitoring of water quality

---

Q5. Children with Fever, Jaundice after Village Fair - Diagnosis, Outbreak Investigation (College of Medicine & Sagore Dutta Hospital) [2+5+3=10]

1. Verification of diagnosis - clinical + LFT (raised bilirubin, ALT/AST), serology (anti-HAV IgM)
2. Confirm the outbreak exists - compare with baseline incidence
3. Define population at risk (children who attended the fair)
4. Rapid case search with epidemiological case sheet
5. Draw epidemic curve - incubation period analysis points to food at the fair
6. Calculate food-specific attack rates for each food item sold
7. Retrospective cohort study among fair attendees to identify implicated food/water source
8. Environmental investigation - water supply used by food stalls, sanitary conditions, stool examination of food handlers
9. Laboratory: Test water samples, food samples; stool cultures of food handlers
10. Report to health authorities; notify CMOH

• Hepatitis A vaccination of children (recommended in high-risk areas)
• Food safety regulations for fairs/markets: mandatory food handler health certificates, safe water use for food preparation
• Safe water supply and sanitation at fair venues
• Health education about hand washing, hygiene, and risk of street food
• Regulation of street food vendors: licensing, training in hygiene practices
• Surveillance system for early detection

---

Q6. Radiation Study Among Nuclear Plant Workers - Cohort Study (JNM Kalyani) [2+8+5=15]

1. Selection of study subjects: Select two cohorts - (a) exposed group: workers with significant radiation exposure in the nuclear plant; (b) unexposed group: administrative/office staff of the same plant or workers in a similar factory without radiation exposure - comparable in age, sex, socioeconomic status
2. Obtaining data on exposure: Radiation dosimetry records; personal dosimeters; environmental monitoring; medical examination records
3. Baseline health assessment: Medical examination of all cohort members at start; document pre-existing diseases; blood counts, chromosomal studies
4. Define outcomes clearly: Specify the health outcomes to be measured (cancers, haematological disorders, cataracts, etc.)
5. Follow-up: Follow all cohort members for 5 years; periodic medical examinations (annually); record any new disease occurrence; minimize losses to follow-up
6. Record keeping: Maintain complete medical records, employment records, radiation exposure records
7. Analysis: Calculate incidence rates in exposed and unexposed groups; calculate Relative Risk (RR) = Incidence in exposed / Incidence in unexposed; calculate Attributable Risk (AR)
8. Control of confounding: Match or statistically adjust for confounders (age, smoking, other occupational exposures)
9. Report: Disseminate findings; make policy recommendations for radiation protection

1. Time consuming and expensive: Requires years of follow-up; large sample size needed
2. Loss to follow-up (attrition): Subjects may leave employment, migrate, die from other causes over 5 years - reduces statistical power and introduces bias
3. Not suitable for rare diseases: Large numbers needed if outcome is rare
4. Changes over time: Changes in diagnostic criteria, treatment practices, or exposure levels during follow-up may confound results
5. Healthy worker effect: Workers in nuclear plants are generally healthier than the general population (pre-employment screening), leading to underestimation of effects
6. Ethical issues: Cannot experimentally increase radiation to study dose-response relationships
7. Changes in exposure: Radiation exposure may change during the study period due to safety improvements (Park's Textbook, Cohort Study)

---

Q7. Case-Control Study - Obesity and Osteoarthritis Knee (PC SEN) [8+4+3=15]

1. Define Cases: Persons aged 35-65 years diagnosed with osteoarthritis of the knee joint (based on clinical and radiological criteria - X-ray showing joint space narrowing, osteophytes) attending orthopaedic OPDs/hospitals
2. Define Controls: Persons aged 35-65 years from the same hospital/community WITHOUT osteoarthritis of the knee, matched for age (±5 years) and sex
3. Matching: Match cases and controls for age and sex to control confounding. Use 1:1 or 1:2 matching ratio (1 case: 2 controls increases power)
4. Sample size calculation: Using appropriate formula based on expected odds ratio, prevalence of obesity, confidence level 95%, power 80%
5. Measure Exposure: Assess obesity (BMI ≥30 or ≥25 for Asians) at study entry. Use questionnaire to collect data on past weight history, diet, physical activity, occupation (joint loading), other risk factors
6. 2×2 Contingency Table:

1. Calculate Odds Ratio (OR) = ad/bc (measure of association in case-control study)
2. Statistical analysis: Chi-square test; logistic regression to control for confounders

1. Relatively quick and inexpensive
2. Requires fewer subjects than cohort studies
3. Particularly suitable for rare diseases or diseases with long latency
4. No attrition problems (no follow-up required)
5. Can study multiple aetiological factors simultaneously
6. Ethical issues minimal

1. Relies on recall (memory bias) - cases remember past obesity/diet better than controls
2. Difficulty in establishing temporal relationship (which came first - obesity or OA?)
3. Selection bias in choosing cases and controls
4. Berkesonian bias (hospital-based case-control)
5. Cannot directly calculate incidence rates or relative risk (only OR)
6. Not suitable for rare exposures
7. Confounding is a major problem

1. Recall (Memory) Bias: Cases tend to recall past exposures better than healthy controls (differential recall)
2. Selection Bias: Cases and controls may not be representative of the general population; systematic difference in characteristics
3. Berkesonian Bias: In hospital-based studies, admission rates differ for different diseases, creating spurious associations
4. Interviewer Bias: Interviewer who knows hypothesis may probe cases more thoroughly than controls
5. Confounding: A third variable (e.g., age, joint loading at work) may be associated with both obesity and OA, distorting the true association

---

Q8. 15-Year-Old Boy - High Fever, Bleeding Gums, Petechial Rash - Dengue (PC SEN) [4+6+5=15]

1. Admit to hospital immediately
2. IV access; send blood for CBC (platelet count, haematocrit), NS1 antigen test, anti-Dengue IgM/IgG, LFT, RFT, blood group
3. IV fluid resuscitation (crystalloids) for dengue shock
4. Platelet transfusion if severe thrombocytopenia with active bleeding
5. Paracetamol for fever (avoid aspirin/NSAIDs)
6. Monitor vitals, urine output, platelet count every 4-6 hours
7. Notify BMOH (mandatory notification)

1. Verify diagnosis - clinically confirm dengue; collect blood samples for confirmation
2. Notify CMOH and State health authorities (dengue is a notifiable disease)
3. Establish an investigation team - rapid response team to the locality
4. Case search - identify all cases in the locality with similar symptoms (active and passive surveillance)
5. Vector surveillance: Entomological survey - Stegomyia indices (House Index, Container Index, Breteau Index) to assess Aedes aegypti density
6. Vector control measures:
   • Source reduction (eliminate larval habitats - empty containers, tires, flower pots)
   • Larval control: temephos in water bodies that cannot be emptied
   • Adult mosquito control: indoor residual spraying (pyrethroid-based); fogging in severely affected areas
7. Health education: Community awareness about dengue, avoiding mosquito bites (repellents, mosquito nets, full-sleeve clothes), removing stagnant water
8. Environmental management: Clean drives, removal of solid waste
9. Line listing of all cases for epidemiological analysis
10. Reporting and documentation

---

Q9. Outbreak of Diarrhoea - Under 5 Children, Purba Bardhaman (Burdwan Medical College) [1+1+8=10]

• Under-5 children: focus on rotavirus, ETEC, Shigella as common causes
• Stool samples from cases for culture and ova/parasite examination
• Water samples from all sources (hand pumps, wells)
• Food history: breast feeding vs. weaning food contamination
• Vector (flies) assessment
• Management: ORS/IV fluids, zinc supplementation (as per IMNCI protocol), continuation of breastfeeding
• Control: Vitamin A supplementation in severely malnourished; safe drinking water; hand washing promotion; latrine construction

---

Q10. 250 Cases Acute Watery Diarrhoea - 5 Deaths; Define Outbreak, Epidemic Curve (IQ City Medical College) [1+6+3+5=15]

• A point-source epidemic (common source - community feast) shows a sharp unimodal bell-shaped curve - rapid rise, single peak, rapid fall
• The peak is within one incubation period of the exposure
• All cases cluster within 1-2 incubation periods of the index exposure date
• The peak date minus the average incubation period of the suspected pathogen = likely exposure date
• The width of the curve reflects the range of incubation periods

• Immediate: ORS/IV fluids, case isolation, notify health authorities
• Water: chlorination of all water sources; boil water advisory
• Food: destroy contaminated food items; health inspection of remaining food
• Sanitation: disinfection of environment with bleaching powder
• Chemoprophylaxis: doxycycline for close contacts if cholera confirmed
• Surveillance: active case finding, line listing
• Long-term: safe water supply, total sanitation, health education

---

Q11. Comparing Two Drugs for Hypertension - Study Design, Steps, Biases (IQ City) [1+6+3=10]

1. Formulate hypothesis: Drug A is superior to Drug B in reducing BP among hypertensives
2. Define eligibility: Inclusion criteria (age, BP criteria e.g., systolic 140-179 mmHg, no contraindications) and exclusion criteria (secondary hypertension, pregnant, comorbidities)
3. Sample size calculation: Based on expected difference in BP reduction, SD, α=0.05, power=80%
4. Ethical approval and informed consent from all participants
5. Randomization: Use computer-generated random numbers to allocate subjects equally to two arms (Drug A group, Drug B group) - this is the HEART of a clinical trial (ensures comparability)
6. Blinding: Ideally double-blind (patient and physician unaware of allocation) to prevent performance and detection bias
7. Intervention: Administer Drug A to Group 1, Drug B to Group 2 for a defined period
8. Follow-up: Measure blood pressure at regular intervals; record compliance, side effects, outcomes
9. Outcome measurement: Primary outcome (reduction in BP), secondary outcomes (cardiovascular events, side effects)
10. Analysis: Intention-to-treat analysis; compare mean BP reduction between groups using t-test or ANCOVA; calculate 95% CI

• Selection bias: Controlled by randomization - ensures comparable groups
• Performance bias: Controlled by blinding of treating physician
• Detection/Observer bias: Controlled by blinding of outcome assessors (double-blind)
• Attrition bias: Loss to follow-up handled by intention-to-treat analysis
• Confounding: Controlled by randomization; residual confounding addressed by stratified analysis

---

Q12. Research Proposal - Prevalence of Hypertension Among Non-Medical Office Staff, BMCH [1+2+7+2+3=15]

• Primary: To determine the prevalence of hypertension among non-medical office staff of BMCH
• Secondary: To identify risk factors (obesity, smoking, alcohol, diet, physical activity, stress) associated with hypertension; to compare prevalence with national/state figures

• Design: Cross-sectional study
• Study population: All non-medical office staff (clerks, administrative staff, peons) of BMCH
• Sample size: Using formula n = Z²pq/d² (assuming p=30% from literature, d=5%, Z=1.96 → n ≈ 323; add 10% non-response = ~355)
• Sampling: Stratified random sampling by department
• Data collection tool: Pretested structured questionnaire + blood pressure measurement (two readings on two separate occasions with mercury sphygmomanometer, after 5 min rest, sitting position)
• Definition of hypertension: BP ≥ 140/90 mmHg on two readings or on antihypertensive medications (JNC-8 / WHO criteria)
• Anthropometric measurements: weight, height, BMI, waist circumference
• Duration: 3-6 months

• Written informed consent from all participants
• Confidentiality of data maintained
• Participants found to be hypertensive will be referred for management
• IEC (Institutional Ethics Committee) approval obtained before commencement
• No risk to participants; benefits: free BP measurement

• Prevalence = (Number with hypertension / Total examined) × 100
• Frequency tables and descriptive statistics
• Chi-square test for association between categorical variables and hypertension
• Logistic regression to identify independent risk factors (OR with 95% CI)
• Software: SPSS/Epi Info; p < 0.05 considered significant

---

Q13. Define Epidemiology; Classify Epidemiological Studies; Steps of Cohort Study; Bias in Cohort Study (MCK) [2+5+5+3=15]

Epidemiological Studies
├── Observational Studies
│   ├── Descriptive Studies
│   │   ├── Case reports / Case series
│   │   ├── Ecological (Correlational) studies
│   │   └── Cross-sectional (Prevalence) studies
│   └── Analytical Studies
│       ├── Case-Control Study (retrospective)
│       └── Cohort Study (prospective/retrospective)
└── Experimental (Interventional) Studies
    ├── Randomized Controlled Trials (RCT)
    │   ├── Clinical trials
    │   └── Field trials
    └── Community Trials (Quasi-experimental)

1. Selection of study subjects: General population or special exposure groups (e.g., factory workers, doctors). Two groups identified: exposed and unexposed (comparable in all aspects except the exposure)
2. Obtaining data on exposure: Personal interviews, mailed questionnaires, medical records, environmental surveys, medical examination/special tests
3. Selection of comparison group: Either (a) internal comparison group (unexposed within the same cohort), or (b) external comparison group (general population rates), or (c) both
4. Follow-up: Both groups observed over time; both exposed and unexposed should be followed with equal intensity; minimize attrition; periodic medical examinations; vital registration
5. Analysis: Calculate incidence rates in exposed and unexposed; compute Relative Risk (RR) = Incidence rate in exposed / Incidence rate in unexposed; Attributable Risk (AR) = Incidence in exposed - Incidence in unexposed; also Population Attributable Risk

1. Selection bias (Healthy Worker Effect): Workers are generally healthier than the general population (pre-employment screening); leads to underestimation of risk
2. Loss to follow-up (attrition) bias: If subjects who are lost differ systematically from those retained, results are biased
3. Surveillance bias (Detection bias): Exposed group may be monitored more intensively than unexposed, leading to more disease detection
4. Information bias: Errors in measuring exposure or outcome
5. Confounding: Unmeasured confounders differentially distributed between exposed and unexposed

---

Q14. Causal Association - OCP and Breast Cancer (ESI Joka) [1+2+6+3+3=15]

1. Select exposed cohort: Women currently using OCPs (no prior breast cancer)
2. Select unexposed cohort: Women never using OCPs, matched for age, parity, menopausal status
3. Baseline assessment: Document OCP use history, duration, type; clinical breast examination; mammography baseline
4. Follow-up: Follow both groups for sufficient time (10-20 years) for breast cancer incidence
5. Record all cases of breast cancer (biopsy-confirmed)
6. Calculate RR = Incidence in OCP users / Incidence in non-users
7. Analyze for confounders: age at menarche, family history, BMI, other hormonal factors

1. Temporal relationship established (exposure precedes disease)
2. Incidence rates and RR can be directly calculated
3. Multiple outcomes can be studied simultaneously
4. Less susceptible to recall bias (exposure recorded prospectively)
5. Can study dose-response relationship (duration of OCP use)

1. Time consuming and expensive
2. Loss to follow-up over long period
3. Not suitable for rare diseases
4. Cannot study rare exposures efficiently
5. Healthy worker/volunteer effect may introduce bias

---

Q15. Rare Fatal Disease Associated with Smoking (Bankura Sammilani) [2+8+5=15]

1. Define cases: All persons diagnosed with the rare disease (use clear diagnostic criteria); identify from hospitals, death registries, cancer registries
2. Select controls: Matched controls (age, sex, hospital) without the rare disease
3. Measure exposure: Detailed smoking history from both cases and controls (type, duration, pack-years) using structured questionnaire
4. Matching: Match for age, sex, and other known confounders
5. Data analysis: 2×2 table; calculate Odds Ratio (OR) = ad/bc; chi-square for significance
6. Control biases: Train interviewers; blind interviewers to case/control status where possible; use hospital records to validate smoking history

1. Ideal for rare diseases - cases can be assembled efficiently
2. Relatively quick and inexpensive
3. Can study multiple exposures (smoking type, alcohol, occupational exposures) simultaneously
4. No attrition problem (no follow-up needed)
5. Ethical - no exposure is applied

1. Cannot calculate incidence rates; only OR (estimate of RR)
2. Recall bias: fatal cases may not be able to give history (proxy recall may be needed)
3. Selection bias in choosing appropriate controls
4. Difficult to establish temporal sequence
5. Cannot study rare exposures

---

Q16. Screen Time and Mental Disorders in Adolescence (College of Medicine & Sagore Dutta) [2+8+2+3=15]

1. Define the cohort: Children in early childhood (e.g., 2-5 years) from a defined geographic area
2. Measure exposure: Screen time duration in hours per day (using structured questionnaire to parents, validated tools); classify into categories (< 1 hr/day, 1-3 hr/day, >3 hr/day)
3. Baseline assessment: Developmental assessment, socioeconomic status, parental education, other screen time characteristics
4. Follow-up: Track cohort until adolescence (10-19 years)
5. Outcome measurement: Use validated tools (SDQ - Strengths and Difficulties Questionnaire; DSM-5 criteria) to identify common mental disorders (anxiety, depression, ADHD, conduct disorders)
6. Confounders: Control for parental mental health, socioeconomic status, physical activity, peer relationships
7. Analysis: Calculate incidence; RR for mental disorders; dose-response analysis (more screen time → more disorders?); Kaplan-Meier survival analysis

1. Attrition (loss to follow-up) bias over long follow-up period in adolescence
2. Information bias in measuring screen time (parental report may be inaccurate)
3. Confounding by parenting style, socioeconomic factors
4. Healthy cohort effect

• Minimize attrition: regular contact, incentives for participation
• Use objective screen time measurement (phone app data, parental logs)
• Stratify analysis and use multivariate regression to control confounders
• Use validated, standardized outcome assessment tools applied by trained psychologists blinded to exposure status

---

Q17. Define Epidemiology; Classify; Describe One Observational Study (Jagannath Gupta) [2+3+10=15]

1. Define the population and study area
2. Formulate objectives and hypothesis
3. Calculate sample size
4. Sampling technique: simple random/stratified/systematic random sampling
5. Develop data collection tools (questionnaire + examination proforma)
6. Ethical approval, informed consent
7. Pilot testing of tools
8. Train data collectors
9. Data collection: interview + clinical examination + investigation
10. Data entry and cleaning
11. Analysis: prevalence estimates; chi-square; logistic regression
12. Interpretation and report writing

---

Q18. Obesity and Hypertension - Cohort Study Data Analysis (Deben Mahata GMC) [1+6+2+2+4=15]

1. Temporal relationship established (obesity measured before hypertension developed)
2. Incidence rates can be directly calculated
3. Multiple outcomes can be studied (hypertension, diabetes, CVD from one cohort)

1. Expensive and time consuming (15 years)
2. Loss to follow-up over long period

• Obese (exposed): 2,000; developed HTN = 200
• Non-obese (unexposed): 4,000; developed HTN = 100

• Incidence in obese = 200/2,000 = 0.10 (10%)
• Incidence in non-obese = 100/4,000 = 0.025 (2.5%)
• Relative Risk (RR) = 0.10/0.025 = 4.0
• Interpretation: Obese individuals have 4 times the risk of developing hypertension compared to non-obese individuals over 15 years
• Attributable Risk (AR) = 10% - 2.5% = 7.5% (excess risk attributable to obesity)
• Population Attributable Risk: Can be calculated based on prevalence of obesity in the population

---

Q19. Alcohol Consumption and Dyslipidaemia - Nested Case-Control (MJN Medical College, Coochbehar) [10]

1. Define cases: Adults in a block of Cooch Behar with dyslipidaemia (total cholesterol >200, LDL >130, TG >150 mg/dL, or on lipid-lowering drugs)
2. Define controls: Age and sex-matched adults in the same block without dyslipidaemia
3. Measure exposure: Detailed alcohol consumption history (type, quantity in standard drinks/week, duration, pattern - binge vs regular)
4. Control confounders: diet, BMI, physical activity, smoking, diabetes, family history

1. Recall bias: Alcohol consumption is under-reported (socially desirable answers)
2. Selection bias: Controls may not be representative
3. Confounding by diet, obesity, smoking
4. Reverse causation: Dyslipidaemia may influence alcohol consumption

---

Q20. Time Trends in Disease Occurrence (R.G. Kar Medical College) [12+3=15]

• Occur over days, weeks, or months
• Examples: Food poisoning outbreaks, cholera epidemics, influenza waves
• Point-source outbreaks show a sharp rise and fall within one incubation period
• Person-to-person propagated epidemics show a gradually rising curve over several incubation periods

• (a) Seasonal variation: Regular increase in disease at certain seasons each year
  • Example: Diarrhoeal diseases (summer/monsoon), respiratory infections (winter), malaria (post-monsoon), dengue (monsoon)
  • Related to seasonal changes in vectors, host behavior, environmental conditions
• (b) Cyclic trends: Regular waves of disease occurrence over several years
  • Example: Measles - 2-yearly cycles; influenza - 3-4 yearly cycles; influenza pandemics every 10-40 years
  • Related to accumulation of susceptibles in the population after each epidemic depletes the immune pool

• Changes in disease frequency over decades
• Example: Tuberculosis declined over 100 years before antibiotics (improvement in living standards); coronary heart disease incidence rose in 20th century; polio eradicated over decades
• Secular trends help identify fundamental changes in host-agent-environment interactions

1. Changes in diagnostic criteria: A disease that appears to be rising may simply be due to changed/improved diagnostic criteria
2. Changes in disease classification: ICD coding changes may alter apparent rates
3. Changes in reporting completeness: Improved surveillance may give impression of increasing incidence
4. Changes in demographic structure: Aging population may increase age-related diseases
5. Changes in population size: Must use rates, not absolute numbers
6. Artefacts: Statistical artefacts, changes in numerator or denominator

---

Q21. Cross-Sectional Survey → Hypothesis: OA Knee Associated with Obesity → Next Study (NRS Medical College) [2+8+5=15]

1. Relatively quick, inexpensive
2. Suitable for chronic diseases with long latency
3. Can study multiple aetiological factors (BMI, diet, occupation)

1. Recall bias for past obesity/weight history
2. Selection bias in case and control selection
3. Cannot calculate incidence rates; only OR; cannot directly establish temporal relationship

---

Q22. Air Pollution and Bronchial Asthma - Cohort Study (Sarat Chandra Chattopadhyay) [3+6+3+3=15]

1. Exposure (air pollution) precedes outcome (asthma) - establishes temporal sequence
2. Long-term exposure study is best studied prospectively
3. Can calculate incidence rates, RR, dose-response relationship
4. Multiple outcomes (asthma, COPD, rhinitis) can be studied in one cohort

1. Select cohort: School-going children (age 5-15 years) from high air pollution area vs. low pollution area; free of asthma at baseline
2. Measure exposure: Ambient air quality monitoring (PM2.5, PM10, NO2, SO2 levels); personal exposure monitoring; duration of outdoor activity
3. Baseline assessment: Lung function tests (spirometry), skin prick tests, serum IgE, questionnaire on symptoms, family history of atopy
4. Follow-up: Annual assessment for 5-10 years; monitor for new-onset asthma (spirometry + clinical diagnosis)
5. Confounders: Document socioeconomic status, indoor air quality, smoking exposure, green space access, diet
6. Analysis: Calculate incidence of asthma in high vs. low pollution groups; RR; dose-response; Cox proportional hazards regression

1. Exposure is measured BEFORE disease occurs - establishes temporal precedence (strongest evidence for causation)
2. Can demonstrate dose-response relationship (more pollution → more asthma)
3. Minimizes recall bias (exposure measured prospectively, not recalled retrospectively)
4. Can satisfy multiple Bradford Hill criteria (temporality, dose-response, consistency)

1. Selection bias: Families who stay in high-pollution areas may differ socioeconomically from those who move away
2. Confounding: Indoor air pollution (cooking fuels, ETS), atopic family history, socioeconomic status
3. Attrition bias: Families may migrate out of the study area during follow-up
4. Information bias: Misclassification of asthma diagnosis (variable diagnostic criteria); exposure misclassification
5. Healthy cohort effect: Initially healthy children selected may not represent all children

---

Q23. Framingham Study - Type, Steps, Advantages, Disadvantages, Causal Association Criteria (KPC Medical College) [1+5+4+5=15]

1. Temporal relationship: exposure before disease
2. Direct incidence rates, RR, AR calculable
3. Multiple risk factors studied in one cohort (smoking, BP, cholesterol, diabetes)
4. Multiple outcomes (MI, stroke, HF, AF) from one cohort
5. Minimizes recall bias

1. Expensive and very time-consuming (decades of follow-up)
2. Loss to follow-up over long periods
3. Not suitable for rare diseases
4. Healthy worker/volunteer effect (Framingham volunteers were healthier than general US population)
5. Results may not be generalizable (Framingham was mostly white population)

1. Strength of association: Strong association (high RR/OR) is more likely to be causal; e.g., RR of 20 for smoking and lung cancer
2. Consistency: The association is repeated in different studies, populations, times, and places
3. Specificity: One cause leads to one effect; e.g., thalidomide causes phocomelia
4. Temporal relationship (Temporality): Cause must precede effect; exposure before disease
5. Biological gradient (Dose-response): Increasing exposure leads to increasing disease; e.g., more cigarettes = more lung cancer
6. Biological plausibility: The association makes biological sense
7. Coherence: The association is consistent with known facts about the natural history of the disease
8. Experiment: Removal of the cause reduces disease (e.g., stopping smoking reduces lung cancer risk)
9. Analogy: Similar associations are known to exist (e.g., thalidomide and phocomelia supports drug-birth defect associations)

---

Q24. Define Epidemic; Types; Epidemiological Investigation of Rash and Fever in Children (CNMC) [2+2+6=10]

1. Common-source (Point-source) epidemic: All cases exposed to same source at one time; sharp unimodal epidemic curve; e.g., food poisoning at a feast
2. Propagated (Person-to-person) epidemic: Spread from person to person; gradually rising epidemic curve with multiple peaks; e.g., measles, chickenpox
3. Mixed epidemic: Starts as common source then spreads person-to-person; e.g., typhoid

• Explosive epidemic (rapid onset)
• Slow epidemic

1. Verify diagnosis: Clinical examination of sample of cases; collect blood for serology (IgM for measles/rubella/varicella), nasopharyngeal swabs for culture; check vaccination status
2. Confirm epidemic: Compare with baseline; check if case numbers exceed expected
3. Define population at risk: School-age children in the block; check vaccination coverage (immunization records)
4. Case search: Active surveillance - school records, PHC records, hospital records; house-to-house survey in affected area
5. Epidemiological case sheet: Name, age, sex, vaccination history, date of onset, rash characteristics, contact history, school attendance
6. Data analysis: Draw epidemic curve; calculate attack rates by age, sex, vaccination status; attack rate in unvaccinated vs. vaccinated (vaccine effectiveness)
7. Hypothesis: If measles - identify gaps in immunization coverage
8. Control measures: Emergency immunization campaign for unvaccinated contacts; isolation of active cases; enhance routine immunization; vitamin A supplementation in measles cases

---

Q25. Immunization Schedule for Infant (KPCMCH) and Eradication of Poliomyelitis

1. Routine Immunization: OPV at birth, 6, 10, 14 weeks; boosters at 16-24 months and 5 years under UIP
2. National Immunization Days (NIDs): Pulse Polio Immunization Programme - supplementary OPV doses given to all children < 5 years on two designated days annually, regardless of prior vaccination status
3. Subnational Immunization Days (SNIDs): Targeted to high-risk areas
4. Switch from OPV to IPV: India introduced fractional IPV (fIPV) intradermally to eliminate Vaccine-Associated Paralytic Poliomyelitis (VAPP)
5. tOPV to bOPV switch: Switched from trivalent OPV to bivalent OPV (types 1 and 3) after type 2 wild poliovirus eradication
6. Acute Flaccid Paralysis (AFP) Surveillance: All AFP cases investigated; stool specimens sent for virology; India certified polio-free in 2014
7. Mop-up operations: Targeted house-to-house immunization in areas with wild poliovirus cases

---

Q26. AEFI Classification (MALDA) [5+5=10]

---

Q27. District with Dengue + Hypertension + Diabetes: Epidemiological Principles (RGKMC) [2+4+6+3=15]

1. Agent (biological cause - pathogen)
2. Host (susceptible person - age, sex, immunity, genetics, nutrition)
3. Environment (physical, biological, social - conditions that influence exposure and susceptibility) Disease occurs when there is imbalance in the triad.

---

Q28. Immunization Drop-Outs and Left-Outs (Jhargram)

• Acceptable dropout rate < 10%; >10% requires action

1. Irregular immunization sessions (vaccine shortage, health worker absence)
2. Poor cold chain maintenance leading to vaccine wastage
3. Inadequate outreach services to remote/tribal areas
4. Health worker attitudes (turning families away)
5. Poor microplanning

1. Lack of awareness about immunization schedule
2. Fear of AEFI (adverse events)
3. Distance to health facility, transport difficulties
4. Opportunity cost (loss of daily wages)
5. Cultural beliefs and misconceptions
6. Migration of families

1. Identify left-outs and drop-outs: Due list preparation; maintain immunization registers; ANMOL (electronic records); village health registers
2. Outreach sessions: Regular outreach to remote areas; mobile immunization units
3. Mobilization: ASHA/AWW for beneficiary tracking; community mobilization through gram sabha
4. Reduce barriers: Multiple vaccines in single visit (missed opportunity prevention); flexible timing of sessions
5. IEC activities: Health education about importance of complete immunization
6. Defaulter tracking: ASHA to follow up families who missed appointments
7. Supervision and monitoring: HMIS data analysis; regular supportive supervision; NIS monitoring
8. Supply chain improvement: Ensure vaccine availability; maintain cold chain; eVIN (Electronic Vaccine Intelligence Network)

---

Q29. 9-Month-Old Child - Anaphylaxis After MR Vaccine (JMN) [2+6+4+3=15]

1. Immediate stabilization and referral (already done - referred to district hospital); continue monitoring
2. AEFI reporting: Fill AEFI reporting form (Form 1); report immediately to BMOH and state immunization officer (serious AEFI = notifiable within 24 hours)
3. AEFI investigation:
   • Complete line list of all children vaccinated from same session
   • Examine the other 4 children with mild reactions (vaccine reaction vs. immunization error)
   • Preserve the vaccine vial(s) and send to state/national vaccine quality control lab with cold chain maintained
   • Investigate the cold chain: temperature logs, vaccine vial monitor (VVM) status
   • Review vaccine preparation and administration technique by health worker
   • Check batch numbers of vaccines used (same batch may have quality defect)
4. Categorize the AEFI: Is this a vaccine product-related reaction (anaphylaxis - true allergic)? Or immunization error (contamination)? The 4 children with mild fever and local swelling suggests vaccine product-related reaction (normal reactions), while the severe child likely had anaphylaxis due to hypersensitivity
5. Causality assessment: Apply WHO causality assessment tool (consistent, inconsistent, indeterminate, unclassifiable)
6. Community communication: Transparent communication with community to prevent panic; avoid suspension of immunization session

1. Pre-immunization screening: Screen for known allergies (especially egg allergy, neomycin allergy, gelatin allergy) before MR vaccination
2. Observation period: Keep all vaccinees under observation for at least 30 minutes after vaccination
3. Anaphylaxis kit: Ensure adrenaline (epinephrine 1:1000) injection is available at every immunization session; train health workers in management of anaphylaxis
4. Functioning hub-cutter: Maintain all safety equipment; use only auto-disabled (AD) syringes
5. Cold chain: Ensure proper cold chain maintenance; check VVM before use; never use vaccine from compromised cold chain
6. Health worker training: Regular training on AEFI recognition, management, and reporting

1. Vaccine product-related: Fever, local pain, febrile seizure (MMR), intussusception (RV vaccine)
2. Vaccine quality defect-related: Reactions from substandard batches
3. Immunization error-related: Abscess (non-sterile injection), TSS (contaminated vial), wrong injection site
4. Immunization anxiety-related (stress-related response): Fainting, syncope, mass hysteria
5. Coincidental events: Not related to vaccine

---

Q30. Electronic Waste Recycling and Chronic Kidney Disease - Study Design, Sampling (RGKMC) [5+4+1=10]

1. Define exposed group: All workers in the e-waste recycling facility handling heavy metals (lead, cadmium, arsenic, mercury)
2. Define unexposed comparison group: Workers in similar industries without heavy metal exposure
3. Baseline assessment: Serum creatinine, GFR, urine protein-creatinine ratio for all workers; urinary heavy metal levels (blood lead, urinary cadmium)
4. Follow-up: Annual kidney function tests; track new CKD cases
5. Outcome: CKD defined as eGFR <60 mL/min/1.73m² for >3 months
6. Calculate RR; adjust for confounders (age, BP, DM, prior kidney disease)

1. Simple Random Sampling: Each member of population has equal chance; uses random number table/computer; best for homogeneous populations
2. Stratified Random Sampling: Divide population into strata (departments, job roles), then random sample from each; ensures representation of all subgroups - most suitable here (stratify by exposure level/job role)
3. Systematic Sampling: Select every kth individual from a list; simple to execute; risk of periodicity bias
4. Cluster Sampling: Divide into clusters (factories, departments); randomly select clusters; all members of selected clusters included; cost-effective for large dispersed populations
5. Multistage Sampling: Combination of above; used in large national surveys
6. Purposive/Convenience Sampling: Non-probability; not preferred for epidemiological research

---

---

SHORT NOTES & EXPLANATIONS

---

SN1. Bias and Confounding are NOT Synonymous (CNMC)

---

SN2. Sentinel Surveillance for Early Outbreak Detection (MCK)

1. Provides timely, quality data before passive surveillance detects the outbreak
2. Sentinel sites (hospitals, labs) have better diagnostic capabilities for confirmation
3. Allows trend monitoring - subtle increases can be detected before full epidemic
4. Cost-effective: Does not require universal reporting; concentrates resources at selected sites
5. Example: Sentinel surveillance for influenza (ILI sentinel sites) detected emergence of H1N1 before widespread transmission; HIV sentinel surveillance at ANC clinics tracks trends

---

SN3. Cohort Study - Gold Standard for Temporal Association but Inappropriate for Rare Disease (College of Medicine & Sagore Dutta)

• Exposure is measured BEFORE disease development - definitively establishes that exposure precedes outcome
• Direct calculation of incidence rates, RR, AR
• Can assess dose-response relationship
• Minimizes recall bias (prospective data collection)
• Example: Framingham Study established that hypertension precedes CVD events

• Rare disease (e.g., aplastic anaemia, rare cancers) has low incidence in population
• To accumulate enough cases for statistical analysis, a HUGE cohort must be enrolled and followed for decades
• Example: If incidence = 1/10,000 per year, to observe 100 cases = need 1,000,000 person-years → 100,000 people for 10 years → prohibitively expensive and impractical
• Case-control study is preferred for rare diseases: starts with existing cases, works backward - efficient, quick, cheap

---

SN4. HPV Vaccination Campaign (CNMC)

• India's UIP Introduction: HPV vaccine (Cervavac - India's first indigenously developed HPV vaccine) introduced in NIS from 2023; targets girls aged 9-14 years (school-based programme)
• Vaccines available: Cervarix (bivalent - types 16,18); Gardasil-4 (quadrivalent - 6,11,16,18); Gardasil-9; Cervavac (quadrivalent)
• Schedule: 2 doses for girls aged 9-14 years (0 and 6 months); 3 doses for ≥15 years
• Route: Intramuscular; deltoid muscle
• Why important: Cervical cancer is the 2nd most common cancer among women in India; HPV types 16 and 18 cause ~70% of cervical cancers; vaccination before sexual debut provides maximum protection
• Complementary to screening: Vaccine + cervical cancer screening (Pap smear/VIA) together for cervical cancer elimination

---

SN5. Relative Risk (RR) Calculation - Silica Dust and Silicosis (Diamond Harbour GMC)

• Incidence in Exposed = 120/800 = 0.15 (15%)
• Incidence in Non-Exposed = 30/1200 = 0.025 (2.5%)
• RR = 0.15 / 0.025 = 6.0

1. Direct calculation of incidence rates and RR (unlike case-control which can only estimate OR)
2. Establishes temporal relationship (exposure precedes disease)

---

SN6. Randomization and Blinding are NOT Used for the Same Purpose (Deben Mahata GMC)

• Purpose: To ensure comparability of groups at baseline (distribution of known AND unknown confounders equally between intervention and control arms)
• When applied: At the time of allocation of subjects to treatment groups (before intervention begins)
• Controls: Selection bias and confounding
• "Randomization is the HEART of a clinical trial" (Park)

• Purpose: To prevent bias during conduct and outcome assessment of the trial
• Applies to: Participants (single blind), investigators/healthcare providers (double blind), outcome assessors, data analysts
• Controls: Performance bias (different care given to groups if provider knows allocation), Detection/Assessment bias (biased outcome measurement), Reporting bias
• Example: Double-blind RCT for analgesic - patient doesn't know if receiving drug or placebo (controls placebo effect); physician doesn't know (prevents differential care)

---

SN7. Open Vial Policy (ICARE)

1. VVM (Vaccine Vial Monitor) has not reached discard point
2. Expiry date not passed
3. Stored under appropriate cold chain conditions
4. No contamination (aseptic technique observed)
5. Vaccine appearance normal

---

SN8. Role of IMG (ICARE)

1. Planning and implementation of Universal Immunization Programme at district/block level
2. Supervision of cold chain and logistics management
3. Training of health workers
4. Monitoring and evaluation of immunization coverage
5. Investigation of AEFIs
6. District immunization coordination

---

SN9. SRS Provides Reliable Estimates of Birth and Death in India (Jhargram GMC)

• A large-scale demographic survey operated by the Office of the Registrar General of India since 1964-65
• A dual record system: continuous enumeration of events (births, deaths) by resident enumerators, supplemented by periodic independent retrospective surveys by supervisors
• Provides annual estimates of birth rates, death rates, infant mortality rates, and total fertility rates at national, state, and rural/urban levels

1. Large sample size: ~7,600+ sample units covering >8 million population - statistically robust
2. Dual recording: Two independent sources matched; reduces errors; events missed in one are captured in the other
3. Continuous registration: Not a one-time census; captures vital events throughout the year
4. Annual data: Provides yearly trend data unlike decennial census
5. Disaggregated data: State-wise and rural/urban breakdowns allow policy planning

---

SN10. Disability and Handicap are NOT Synonymous (SCCMCH)

• Impairment: Structural damage to the spinal cord (L1)
• Disability: Cannot walk (functional limitation)
• Handicap: Cannot attend school or work (social disadvantage)

---

SN11. Case Fatality Rate (CFR) is a Misnomer (SCCMCH)

1. A true rate requires a time dimension (events per unit time)
2. CFR has no time component in its denominator - it is simply a ratio (deaths/cases)
3. It is correctly called Case Fatality Ratio or Case Fatality Proportion

• The denominator (diagnosed cases) depends on diagnostic sensitivity - mild cases may be undiagnosed, inflating or deflating the CFR
• CFR varies with disease severity, treatment quality, and case ascertainment
• Example: Ebola CFR = 50-90% (severe, highly fatal); common cold CFR ≈ 0 (mild)

---

SN12. AEFI Tracking Protocols Extend Beyond Direct Pharmacological Side Effects (IPGMER)

1. Temporal association, not causal: Any event following immunization is reported, even if causality is NOT established (to avoid missing true signals)
2. Includes coincidental events: Events unrelated to vaccine are also tracked to distinguish from causal reactions
3. Includes program errors: Errors in vaccine handling, preparation, administration that are NOT properties of the vaccine itself
4. Includes anxiety reactions: Psychological responses (fainting, hyperventilation, mass psychogenic illness) that are not pharmacological
5. Cluster detection: Unusual clustering of events in time and place is tracked even if individual events seem minor
6. Public trust function: Comprehensive AEFI surveillance maintains public confidence in immunization programmes by demonstrating safety monitoring

---

SN13. Cold Chain System in UIP (MALDA)

• ILR (Ice-Lined Refrigerator): Maintains temperature at +2 to +8°C; used for liquid vaccines
• Deep Freezer: Maintains -15 to -25°C; used for OPV (freeze-dried)
• Vaccine Carrier: Portable insulated box with 4 ice packs; 4-6 hours temperature maintenance for field sessions
• Cold Box: Larger insulated box; 24-48 hours maintenance; used for transportation
• VVM (Vaccine Vial Monitor): Heat-sensitive label on vials that changes color if vaccines have been exposed to excessive heat; ensures potency
• eVIN (Electronic Vaccine Intelligence Network): Digital system for real-time tracking of vaccine stocks and temperatures across India
• Thermometer/Temperature logs: Twice daily temperature recording at all levels

---

SN14. Standard Error (Midnapore)

1. SE decreases as sample size increases (larger samples give more precise estimates) - important in planning sample size
2. SE is used to construct 95% Confidence Intervals: Mean ± 1.96 × SE
3. SE is NOT the same as standard deviation (SD):
   • SD measures variability within a sample
   • SE measures uncertainty/precision of the sample mean as an estimate of the population mean
4. Used in hypothesis testing: test statistic = (observed - expected) / SE

---

SN15. RR and AR are NOT Synonymous (Midnapore)

• RR = Incidence in exposed / Incidence in unexposed
• Measures the strength of association between exposure and disease
• A dimensionless ratio; RR = 1 (no association), >1 (increased risk), <1 (protective)
• Used to communicate biological significance, causation
• Example: RR = 10 for smoking and lung cancer = smokers have 10× the risk

• AR = Incidence in exposed - Incidence in unexposed
• Measures the additional risk (excess cases) attributable to the exposure
• Has units (cases per 1,000 per year etc.)
• Measures public health significance - how many cases can be prevented by removing exposure
• Example: AR = 48/1,000/year for smoking and lung cancer = 48 extra cases per 1,000 smokers per year attributable to smoking

---

SN16. Incidence Preferred Over Prevalence in Studying Disease Causation (JNM Kalyani)

1. Temporal sequence: Incidence captures NEW cases, allowing exposure to precede disease - essential for establishing causation
2. Unaffected by disease duration: Prevalence = Incidence × Duration; therefore prevalence is influenced by both disease occurrence AND survival/recovery - confounds the study of causes
3. Direct measure of risk: Incidence = probability of getting disease; can be used to directly calculate RR, AR
4. Not distorted by treatment: Effective treatment reduces disease duration → reduces prevalence even without reducing incidence (disease still occurring at same rate but cases recovering faster); incidence is unaffected

---

SN17. OPV Administered at Birth Despite Subsequent Doses Being Scheduled (Tamralipto) [4 Marks]

1. Herd immunity contribution: Birth dose helps achieve higher coverage population-wide; early colonization of gut by vaccine strains blocks wild poliovirus
2. Passive immunity present in early life: Maternal antibodies may interfere with OPV if given at 6 weeks; however, the birth dose given BEFORE maternal antibodies decline can still prime gut-associated immune tissue (GALT)
3. Boosts mucosal (secretory IgA) immunity in gut: OPV induces local intestinal immunity against poliovirus; early birth dose primes gut mucosal immunity even if systemic response is weak; subsequent doses at 6, 10, 14 weeks boost systemic and mucosal immunity
4. In India's endemic context: Historically polio was endemic; early protection was needed; even if systemic seroconversion is not guaranteed at birth (maternal antibodies), the gut priming is valuable
5. Overall immunogenicity is enhanced: Even if birth dose alone doesn't provide full protection, it contributes to higher final antibody titres when subsequent doses are given at 6, 10, 14 weeks

---

SN18. Hepatitis B Vaccine Given Within 24 Hours of Birth (Sanaka) [4 Marks]

1. Prevention of perinatal transmission: The most important route of HBV transmission in high-prevalence countries is mother-to-child (perinatal) transmission; 90% of infants infected perinatally become chronic carriers. Birth dose is critical to interrupt this.
2. High risk at birth: If mother is HBsAg positive (especially if HBeAg positive), infant is at very high risk of infection during delivery (exposure to infected blood and secretions)
3. Time-sensitive protection: HBV vaccination within 24 hours (ideally <12 hours) of birth, combined with HBIG (hepatitis B immunoglobulin), is >90% effective in preventing perinatal transmission
4. Antibody development is fast: The vaccine starts inducing immunity relatively quickly; starting early maximizes the protection window before repeated environmental exposures
5. Universal birth dose: Since maternal HBsAg status may not always be known (especially in resource-poor settings), universal birth dose policy protects ALL infants regardless of maternal status
6. Long-term protection: Perinatal HBV infection leads to chronic HBV → cirrhosis → hepatocellular carcinoma; preventing perinatal infection prevents long-term complications

---

SN19. HPV Vaccine - Short Note (Midnapore) [5 Marks]

• Mechanism: Virus-Like Particle (VLP) vaccine - no live virus; induces neutralizing antibodies against L1 capsid protein of HPV
• Efficacy: >95% effective against HPV 16 and 18 cervical lesions if given before sexual exposure
• Safety: Generally safe; common reactions - pain, redness at injection site, mild fever; rare - AEFI
• India: CERVAVAC (Serum Institute of India) - first Indian HPV vaccine; quadrivalent (types 6, 11, 16, 18); available in NIS since 2023

---

SN20. Source and Reservoir of Disease are NOT the Same (PC SEN) [4 Marks]

---

SN21. The "5 F's" in Fecal-Oral Disease Transmission (PC SEN) [4 Marks]

1. Fluids (Water): Contaminated drinking water - most common vehicle for cholera, typhoid, hepatitis A, diarrhoeal diseases
2. Fingers: Poor hand hygiene - feces on fingers → mouth; especially important in children
3. Flies: Mechanical vectors carrying pathogens from feces to food; houseflies spread typhoid, dysentery, cholera
4. Fields (Faeces/Soil): Night soil (human excreta used as manure) contaminating crops; hookworm, Ascaris from soil
5. Food: Food contaminated during preparation, storage, or by infected food handlers; most food-borne outbreaks

---

SN22. Left-Out and Drop-Out Children are Different in Immunization (RGMCH) [4 Marks]

• Left-out: Never received ANY vaccine; NOT reached by programme
• Drop-out: Received some doses but incomplete schedule (started, did not finish)

• Left-outs: Need outreach, community mobilization, addressing access barriers
• Drop-outs: Need tracking, reminder systems, defaulter follow-up, addressing reasons for discontinuation

---

SN23. "Serious" and "Severe" are NOT the Same in AEFI (IQCMC) [4 Marks]

• Results in death
• Is life-threatening
• Requires hospitalization or prolongation of existing hospitalization
• Results in persistent or significant disability/incapacity
• Is a congenital anomaly/birth defect
• Is an important medical event (may jeopardize patient or require medical intervention to prevent above outcomes)

• Grade 1 (Mild): Easily tolerated; minor symptoms
• Grade 2 (Moderate): Sufficient discomfort to interfere with daily activity; Grade 3 (Severe): Prevents daily activity; Grade 4 (Life-threatening)

• A severe local reaction (extensive swelling of the limb after DPT) is severe (grade 3 intensity) but may NOT be serious (does not require hospitalization)
• A mild anaphylaxis promptly treated and recovered fully may be classified as serious (life-threatening potential) but not "severe" in terms of intensity after treatment

---

SN24. Random Sampling Preferred Over Convenience Sampling (MCK) [4 Marks]

1. Representativeness: Random samples are representative of the population; allows generalization of findings (external validity)
2. Eliminates selection bias: No systematic over- or under-representation of any group
3. Statistical validity: Probability theory and inferential statistics (confidence intervals, p-values, significance tests) are based on the assumption of random sampling; results from convenience samples cannot be validly analyzed using standard statistical methods
4. Reproducibility: Other researchers using random sampling from the same population should get similar results
5. Allows error estimation: Sampling error (random variation) can be calculated and reported as confidence intervals; with convenience sampling, error cannot be meaningfully estimated

---

SN25. Purpose of Vaccination - Individual AND Community Protection (ESI Joka)

• When a high proportion of the population is immune, transmission chains are broken
• Even unvaccinated/unimmunizable persons (newborns, immunocompromised, allergic) are protected indirectly because vaccinated people do not transmit the agent
• Herd immunity threshold: The minimum proportion needing immunity to interrupt transmission = 1 - (1/R₀), where R₀ is the basic reproduction number
  • Measles (R₀=12-18): Herd immunity threshold ≈ 92-95%
  • Polio (R₀=5-7): Threshold ≈ 80-85%
  • COVID-19 (R₀~2-3): Threshold ≈ 50-67%
• Reduces disease load: When vaccination coverage is high, overall incidence falls → fewer cases → less spread → eventually potential eradication
• Protects vulnerable populations: Elderly, infants, immunocompromised benefit from herd immunity even if they cannot be vaccinated
• Examples: Smallpox eradicated; polio near eradication; measles incidence dramatically reduced - all through herd immunity from vaccination

---

SN26. Randomization is the Heart of Clinical Trial (Barasat GMC / Gouri Devi)

1. Distributes both known and unknown confounders equally between treatment groups at baseline - something no other method achieves
2. Creates genuinely comparable groups - any observed difference in outcome can be attributed to the treatment
3. The scientific foundation of causal inference in clinical trials
4. Allows use of probability theory in statistical analysis
5. Without randomization: selection bias can make a useless or harmful treatment appear effective, or an effective treatment appear useless

• Simple randomization (coin flip, random number table)
• Block randomization (ensures equal allocation in small samples)
• Stratified randomization (ensures balance on important prognostic factors)
• Minimization (adaptive randomization)

---

SN27. Monitoring and Surveillance are NOT Synonymous (Jhargram GMC)

---

SN28. Informed Consent in Epidemiological Research (North Bengal Medical College)

1. Disclosure: Full information about study purpose, procedures, duration, expected benefits and risks
2. Comprehension: Information given in participant's language; understanding confirmed
3. Voluntariness: No coercion, undue influence, or pressure to participate
4. Competence: Participant must be mentally capable; for children/incompetent adults, consent from guardian (assent from child ≥7 years also taken)
5. Decision and Authorization: Written (or documented verbal with witness) consent; participant may withdraw at any time without penalty

• Ethical mandate: Declaration of Helsinki, ICMR Guidelines, GCP guidelines
• In cross-sectional/cohort/case-control studies: questionnaires, clinical data collection require consent
• Community trials: Community consent + individual consent both needed
• Special issues: Vulnerable populations (prisoners, pregnant women, children) require extra protection

---

SN29. Population Attributable Risk (KPC Medical College)

• PAR (absolute) = Incidence in total population - Incidence in unexposed
• PAR% = (Incidence in total population - Incidence in unexposed) / Incidence in total population × 100
• Alternative: PAR% = Pe(RR - 1) / [Pe(RR - 1) + 1] × 100 (where Pe = prevalence of exposure in population)

---

SN30. Epidemiologically Carrier is More Important than Cases (Jagannath Gupta)

1. Not identified or isolated: Cases are symptomatic and get treated/isolated; carriers are healthy and freely move in the community, continuously shedding pathogens
2. Large numbers: For every symptomatic case, there may be hundreds or thousands of carriers (iceberg phenomenon) - e.g., for every clinical typhoid case, there are multiple carriers
3. Long duration of shedding: Chronic carriers (e.g., typhoid: gallbladder carriage; HBV: chronic hepatitis B) shed for years to decades; cases shed only during illness
4. Difficult to detect: No symptoms → no medical care → not diagnosed; special surveillance needed
5. Maintenance of disease in community: Carriers maintain the reservoir and ensure continuous transmission; without carriers, many diseases would die out between epidemics
6. Example: Typhoid Mary (Mary Mallon) - asymptomatic typhoid carrier who infected 51 people as a cook

---

SN31. Influenza Vaccine Must Be Taken Yearly (NBMC)

1. Antigenic drift: Influenza virus undergoes continuous minor mutations in surface antigens (hemagglutinin, neuraminidase) - antigenic drift. Each year's circulating strain may differ from the previous year's vaccine strain; annual reformulation to match circulating strains
2. WHO surveillance: WHO Global Influenza Surveillance and Response System (GISRS) monitors circulating strains worldwide and recommends vaccine composition twice yearly (February for Northern Hemisphere, September for Southern Hemisphere)
3. Waning immunity: Even if the strain doesn't change, antibody levels from previous vaccination wane over 6-12 months; annual booster maintains protective levels
4. High-risk groups: Elderly, healthcare workers, pregnant women, immunocompromised, patients with chronic diseases should receive annual dose
5. Pandemic preparedness: Annual vaccination maintains manufacturing infrastructure and surveillance systems needed for rapid response to pandemic strains (antigenic shift)

---